We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

207 hedge funds and large institutions have $3.29B invested in Neurocrine Biosciences in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 78 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $65M | Put options by funds: $28.8M

43% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 23

5% more funds holding

Funds holding: 198 → 207 (+9)

4% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 78

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

17% less capital invested

Capital invested by funds: $3.98B → $3.29B (-$691M)

Holders
207
Holders Change
+9
Holders Change %
+4.55%
% of All Funds
5.78%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
33
Increased
81
Reduced
78
Closed
23
Calls
$65M
Puts
$28.8M
Net Calls
+$36.2M
Net Calls Change
-$6.56M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$87.9M
2
CCI
Columbus Circle Investors
+$22.4M
3
TCP
Tourbillon Capital Partners
New York
+$21.9M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$19.3M
5
CCM
Cadian Capital Management
New York
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$82.1M
2
O
OrbiMed
New York
-$61.8M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$49.5M
4
PA
Perceptive Advisors
New York
-$16.5M
5
Citadel Advisors
Citadel Advisors
Florida
-$16.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAMS
101
Bellevue Asset Management (Switzerland)
Switzerland
$2.59M – – –
CCM
102
Cupps Capital Management
Illinois
$2.37M +$2.87M +59,465 New
MLICM
103
Metropolitan Life Insurance Company (MetLife)
New York
$2.34M +$9.23K +191 +0.3%
PA
104
Profund Advisors
Maryland
$2.31M +$2.81M +58,101 New
EI
105
EAM Investors
California
$2.3M -$649K -13,421 -19%
Canada Pension Plan Investment Board
106
Canada Pension Plan Investment Board
Ontario, Canada
$2.27M +$2.76M +57,025 New
GTC
107
Ghost Tree Capital
New York
$2.19M -$3.26M -67,500 -55%
DBG
108
De Burlo Group
Massachusetts
$2.12M -$193K -4,000 -7%
AIG
109
American International Group
New York
$2.05M -$790K -16,345 -24%
ACM
110
Asymmetry Capital Management
California
$1.97M +$2.39M +49,500 New
PNC Financial Services Group
111
PNC Financial Services Group
Pennsylvania
$1.97M +$902K +18,660 +61%
RFC
112
Russell Frank Company
Washington
$1.92M +$348K +7,202 +18%
PP
113
PDT Partners
New York
$1.91M -$19.3K -400 -0.8%
TI
114
Trexquant Investment
Connecticut
$1.9M +$193K +4,000 +9%
Morgan Stanley
115
Morgan Stanley
New York
$1.87M +$777K +16,076 +52%
NCGI
116
Next Century Growth Investors
Minnesota
$1.86M +$2.26M +46,821 New
BlackRock
117
BlackRock
New York
$1.86M -$355K -7,337 -14%
SFP
118
Santa Fe Partners
New Mexico
$1.85M +$862K +17,841 +62%
ACI
119
Alpha Cubed Investments
California
$1.77M – – –
SEI Investments
120
SEI Investments
Pennsylvania
$1.73M +$1.72M +35,633 +461%
DekaBank Deutsche Girozentrale
121
DekaBank Deutsche Girozentrale
Germany
$1.71M +$72.5K +1,500 +4%
GCP
122
GSA Capital Partners
United Kingdom
$1.65M +$1.46M +30,150 +269%
First Manhattan
123
First Manhattan
New York
$1.64M -$5.36M -111,000 -73%
CSS
124
Cubist Systematic Strategies
Connecticut
$1.63M +$763K +15,793 +62%
QIM
125
Quantitative Investment Management
Virginia
$1.55M +$1.5M +31,100 +394%
3 4
5
6 7

NBIX Hedge Fund Activity: Q3 2015 in Review

207 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2015, worth a combined $3.29B — down 17% from $3.98B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new NBIX positions and 23 closed out — a net gain of 10 holders — while 81 added to existing stakes and 78 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $87.9M. The largest seller was PointState Capital, cutting an estimated $82.1M.

  • 207 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2015, up from 198 in Q2 2015.
  • Funds reported $3.29B of Neurocrine Biosciences stock for Q3 2015, down 17% quarter-over-quarter.
  • 33 funds opened new Neurocrine Biosciences positions in Q3 2015 and 23 closed out, a net change of +10 holders.
  • The largest Neurocrine Biosciences buyer in Q3 2015 was Fidelity Investments, an estimated $87.9M added.
  • The largest Neurocrine Biosciences seller in Q3 2015 was PointState Capital, an estimated $82.1M sold.

Based on aggregated 13F filings for Q3 2015.